Valuation Gilead Sciences, Inc. Buenos Aires S.E.

Stocks

End-of-day quote Buenos Aires S.E. 2026-09-08			5-day change	1st Jan Change
58,200.00 ^ARS	-3.48%		-2.18%	+24.20%

09-08	Assembly Biosciences Exercises Option to Share US Costs, Profits for Herpes Program With Gilead	MT
09-08	Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead	DJ

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	91,081	107,677	100,942	115,118	152,281	181,827	-	-
Change	-	18.22%	-6.25%	14.04%	32.28%	19.4%	-	-
Enterprise Value (EV) ¹	118,530	126,522	118,665	131,838	169,585	198,572	190,952	184,662
Change	-	6.74%	-6.21%	11.1%	28.63%	17.09%	-3.84%	-3.29%
P/E	14.7x	23.6x	18x	243x	18.1x	-44.8x	18.3x	16.8x
PBR	4.32x	5.05x	4.48x	5.98x	6.73x	9.98x	7.57x	6.04x
PEG	-	-0.9x	0.8x	-2.7x	0x	0x	-0x	1.97x
Capitalization / Revenue	3.34x	3.95x	3.72x	4x	5.17x	5.93x	5.56x	5.29x
EV / Revenue	4.34x	4.64x	4.38x	4.59x	5.76x	6.47x	5.84x	5.38x
EV / EBITDA	8.12x	8.86x	9.01x	11.7x	10.6x	25.3x	10.7x	10.1x
EV / EBIT	9.45x	10.4x	11.3x	15.5x	12.9x	61.5x	12.1x	10.9x
EV / FCF	11x	15.2x	16x	12.8x	17.9x	-377x	14.6x	13.3x
FCF Yield	9.12%	6.59%	6.25%	7.82%	5.58%	-0.27%	6.85%	7.51%
Dividend per Share ²	2.84	2.92	3	3.08	3.16	3.296	3.396	3.102
Rate of return	3.91%	3.4%	3.7%	3.33%	2.57%	2.25%	2.32%	2.12%
EPS ²	4.93	3.64	4.5	0.38	6.78	-3.273	8.021	8.705
Distribution rate	57.6%	80.2%	66.7%	811%	46.6%	-101%	42.3%	35.6%
Net sales ¹	27,305	27,281	27,116	28,754	29,443	30,688	32,679	34,344
EBITDA ¹	14,598	14,283	13,177	11,287	15,953	7,859	17,834	18,324
EBIT ¹	12,548	12,180	10,484	8,520	13,193	3,226	15,830	16,887
Net income ¹	6,225	4,592	5,665	480	8,510	-4,275	10,275	10,917
Net Debt ¹	27,449	18,845	17,723	16,720	17,304	16,745	9,125	2,835
Reference price ²	72.61	85.85	81.01	92.37	122.74	146.64	146.64	146.64
Nbr of stocks (in thousands)	1,254,384	1,254,244	1,246,042	1,246,266	1,240,680	1,239,955	-	-
Announcement Date	2/1/22	2/2/23	2/6/24	2/11/25	2/10/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
ELI LILLY AND COMPANY	32.72x	11.9x	24.26x	0.6%	1,024B
JOHNSON & JOHNSON	30.62x	-	-	1.95%	663B
ABBVIE INC.	32.73x	7.6x	15.8x	2.67%	453B
ROCHE HOLDING AG	19.22x	4.69x	11.6x	2.83%	349B
NOVARTIS AG	22.02x	5.68x	14.1x	2.82%	295B
ASTRAZENECA PLC	20.97x	4.3x	12.3x	2.05%	253B
AMGEN INC.	27.66x	7.14x	13.16x	2.31%	236B
NOVO NORDISK A/S	13.33x	4.82x	10.06x	3.78%	206B
GILEAD SCIENCES, INC.	-46.14x	6.65x	25.95x	2.18%	187B
Average	17.01x	6.60x	15.90x	2.35%	407.48B
Weighted average by Cap.	23.94x	7.98x	17.77x	1.96%